Whitehawk Therapeutics
Update in progressWHWK (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Whitehawk Therapeutics, Inc. is a clinical-stage oncology company focused on developing technologies that define tumor biology to guide cancer treatments. It offers a portfolio of three next-generation antibody-drug conjugates (ADCs). The company was formerly Aadi Bioscience, Inc., changing its name to Whitehawk Therapeutics in August 2021. It was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.16
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.09
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. David J. Lennon Ph.D.
- Founded2007
- Employees32
- Websiteir.whitehawktx.com
Identifiers
- ISINUS00032Q1040
- FIGIBBG002WN7DT2